

# Fine Mapping With TWAS Results Across Multiple Tissues

Shuai Li, Xinyu (Brian) Guo

Johns Hopkins Bloomberg School of Public Health

May 14, 2021

- 1 Background and Methods
- 2 Data For Alzheimer's Disease
- 3 Analysis (SuSiE)
- 4 Reference

# Section 1

## Background and Methods

# What is TWAS?

- TWAS: transcriptome-wide association study.
- To determine significant trait-expression associations. <sup>1</sup>
- This method increases the power of identifying functionally relevant loci by leveraging expression quantitative trait loci (eQTLs) from external references in relevant tissues. <sup>2</sup>

---

<sup>1</sup>Gusev et al. “Integrative approaches for large-scale transcriptome-wide association studies” 2016 Nature Genetics

<sup>2</sup>Bhattacharya et al. “A framework for transcriptome-wide association studies in breast cancer in diverse study populations” 2020 Genome Biology

# TWAS/FUSION Software

- Functional Summary-based Imputation:

FUSION is a suite of tools for performing a TWAS by predicting functional/molecular phenotypes into GWAS using only summary statistics (usually from GWAS). The goal is to identify associations between a GWAS phenotype and a functional phenotype that was only measured in reference data. <sup>1</sup>

---

<sup>1</sup>Gusev et al. “Integrative approaches for large-scale transcriptome-wide association studies” 2016 Nature Genetics

# TWAS/FUSION Software

- Inputs:
  - GWAS summary statistics
  - Reference panels (i.e. precomputed functional weights (primarily gene expression) from multiple tissues)
  - Reference LD data
- Outputs:
  - A data frame with corresponding z and p values for each SNPs.

---

<sup>1</sup>Gusev et al. “Integrative approaches for large-scale transcriptome-wide association studies” 2016 Nature Genetics

# Bayesian Fine Mapping

- Why fine-map?
  - To find causal genes
  - To pinpoint variant
  - To understand genetic architecture
    - Gene enrichment
    - Cross-trait comparison, cross-tissue
- Bayesian fine-mapping outputs:
  - PIP: Posterior inclusion probability (the probability that a variant is causal)
  - 95% Credible Sets: Set of variants that contains  $\geq 95\%$  probability

# Bayesian Fine Mapping

- Single-causal-variant PIPs:

$$\begin{aligned}PIP_j &= P(j \text{ causal} \mid \text{data}) \\&= \frac{P(\text{data} \mid j \text{ causal})}{\sum_k P(\text{data} \mid k \text{ causal})} \\&= \frac{P(\text{data} \mid j \text{ causal})/P(\text{data}|\text{no}\text{causal})}{\sum_k P(\text{data} \mid k \text{ causal})/P(\text{data}|\text{no}\text{causal})} \\&= \frac{\text{Bayesian Factor}_j}{\sum_k \text{Bayesian Factor}_k}\end{aligned}$$



# Bayesian Fine Mapping

- 95% Credible Sets (S):

$$P(\text{causal var is in } S) \geq 0.95$$

- Under Single-causal-variant assumption:

$$P(\text{causal var is in } S) = \sum_{j \in S} PIP_j$$

- To get the most compact credible set, add variant with highest PIPs until sum to 0.95.

# Bayesian Fine Mapping

- Factors affecting Bayesian fine mapping power
  - LD
  - Sample Size
  - Effect size

---

<sup>4</sup>Schaid et al. Nat Rev Genet 2018

# Bayesian Fine Mapping

- Multiple-causal-variant Fine-mapping (two approaches):
  - Divide the whole data into many pieces, and apply single-causal-variant fine-mapping in each piece
  - Jointly model Multiple-causal-variant

## Section 2

# Data For Alzheimer's Disease

# Overview

- Data
  - Gene Expression Matrix: Gene expression level in each tissue
    - Z-values
    - P-values
  - Correlation matrix: Correlation of expression in each tissue for each gene

## Gene Expression matrix

```
dim(dat_ad_n[[1]])
```

```
## [1] 33960    49
```

```
dim(dat_ad_n[[2]])
```

```
## [1] 33960    49
```

```
dat_ad_n[[1]][1:5,1:5]
```

##	GENE	Whole_Blood	Vagina	Uterus	Thyroid
## 1	EXOC3L2	23.14987	NA	9.249285	NA
## 2	CLASRP	12.86142	NA	30.900394	10.092551
## 3	TRAPPC6A	11.31097	1.770764	NA	6.203560
## 4	NKPD1	10.63722	NA	NA	2.276769
## 5	CEACAM19	10.52064	NA	6.806502	10.630916

## Gene Expression matrix

```
dat_ad_n[[2]][1:5,1:5]
```

```
##          GENE Whole_Blood Vagina      Uterus  Thyroid
## 1  EXOC3L2    7.29e-119      NA  1.13e-20      NA
## 2   CLASRP    3.71e-38      NA  5.90e-210  2.98e-24
## 3 TRAPPC6A    5.79e-30  0.0383      NA  2.76e-10
## 4   NKPD1    1.00e-26      NA      NA  1.14e-02
## 5 CEACAM19    3.47e-26      NA  5.00e-12  1.07e-26
```

```
1 - pnorm(dat_ad_n[[1]][3,"Vagina"])
```

```
## [1] 0.0383
```

# Correlation matrix

```
length(cov_matrix)
```

```
## [1] 33994
```

```
names(cov_matrix)[1:10]
```

```
## [1] "MCF2L2" "TRMT10C" "COR01A" "CTD-2026D20.2"
```

```
## [5] "THOP1" "RP11-731K22.1" "DBNDD2" "VPL1-2026D20.2"
```

```
## [9] "PDCD5" "CTD-2026D20.2"
```

```
#Obtain correlation
```

```
gene = 'EXOC3L2'
```

```
cor_matrix <- cov2cor(cov_matrix[[gene]])
```



## Correlation matrix

```
dim(cor_matrix)
```

```
## [1] 23 23
```

```
round(cor_matrix[15:18,15:18],3)
```

##	Liver	Lung	Pancreas	Pituitary
## Liver	1.000	0.401	0.053	0.003
## Lung	0.401	1.000	0.120	-0.143
## Pancreas	0.053	0.120	1.000	-0.137
## Pituitary	0.003	-0.143	-0.137	1.000

## Section 3

### Analysis (SuSiE)

# SuSiE

```
devtools::install_github("stephenslab/susieR")  
library(susieR)  
fitted_rss <- susie_rss(z-scores, R, L = 10)
```

- z-scores: A p-vector of z scores
- R: p by p correlation matrix
- L: Maximum number of components model (Credible Sets).

# Implementation

- `run_susie`
  - Pre-process data
    - Drop NA in expression z-scores vector
    - Take out the common tissue information from expression vector and correlation matrix.
  - Fit model: `susie_rss(z-scores, R, L=4)`
    - Expression z-score matrix is of length  $p$
    - Correlation matrix is  $p$  by  $p$  matrix
    - They contain same tissue information
    - $L=4$

# Main logic

We loop through all genes. For each gene, we implement `run_susie`, and take out the significant tissues in Credible Sets (cs), as well as their Posterior inclusion probability (PIP) scores. We stored these information in a csv file.


# Result

```
head(all_res)
```

##	X	variable_prob	cs	tissues	GENE
## 1	1	1.0000000	1	Whole_Blood	EXOC3L2
## 2	2	1.0000000	2	Adipose_Subcutaneous	EXOC3L2
## 3	3	0.9999839	4	Testis	EXOC3L2
## 4	4	0.9933120	3	Heart_Left_Ventricle	EXOC3L2
## 5	5	1.0000000	1	Uterus	CLASRP
## 6	6	1.0000000	2	Thyroid	CLASRP


# Result

```
plot_pip('CD3EAP',dat_ad,cov_matrix,all_res)
```



# Result


```
plot_pip('HLA-DRB1', dat_ad, cov_matrix, all_res)
```






## Result

```
plot_pip('HLA-DQA2',dat_ad,cov_matrix,all_res)
```



# Result

```
plot_pip('HLA-DRA', dat_ad, cov_matrix, all_res)
```



## Section 4

## Reference

## Reference

- Gusev et al. “Integrative approaches for large-scale transcriptome-wide association studies” 2016 Nature Genetics
- Wang, G., Sarkar, A., Carbonetto, P., & Stephens, M. (2020). A simple new approach to variable selection in regression, with application to genetic fine mapping. Journal of the Royal Statistical Society: Series B (Statistical Methodology). <https://doi.org/10.1111/rssb.12388>
- Schaid, D.J., Chen, W. & Larson, N.B. From genome-wide associations to candidate causal variants by statistical fine-mapping. Nat Rev Genet 19, 491–504 (2018). <https://doi.org/10.1038/s41576-018-0016-z>
- ▶ Hilary Finucane, Broad Institute